Ipsen Stock

Ipsen EBIT

The EBIT of Ipsen (IPN.PA) as of Aug 1, 2026 is 746.30 M EUR. In the previous year, EBIT was 496.70 M EUR — a change of 50.25% (higher).

EBIT

746.30 MEUR

YoY

50.25%

Last updated:

In 2026, Ipsen's EBIT was 746.30 M EUR, a 50.25% increase from the 496.70 M EUR EBIT recorded in the previous year.

The Ipsen EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (B EUR)
Date
EBIT (B EUR)
Jan 1, 2023
0.82 base
Jan 1, 2024
0.50 base
Jan 1, 2025
0.75 base
Jan 1, 2026 (e)
1.01 base
Jan 1, 2027 (e)
1.05 base
Jan 1, 2028 (e)
1.09 base
Jan 1, 2029 (e)
1.16 base
Jan 1, 2030 (e)
1.17 base
YEAREBIT (B EUR)
2030 est 1.17
2029 est 1.16
2028 est 1.09
2027 est 1.05
2026 est 1.01
2025 0.75
2024 0.50
2023 0.82
2022 0.94
2021 0.89
2020 0.76
2019 0.70
2018 0.56
2017 0.40
2016 0.35
2015 0.31
2014 0.25
2013 0.23
2012 0.11
2011 0.08
2010 0.13
2009 0.17
2008 0.18
2007 0.21
2006 0.19
Access this data via the Eulerpool API

Ipsen Revenue

Ipsen Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
3.31 B EUR
816.00 M EUR
644.40 M EUR
Jan 1, 2024
3.57 B EUR
496.70 M EUR
345.90 M EUR
Jan 1, 2025
3.68 B EUR
746.30 M EUR
444.50 M EUR
Jan 1, 2026 (e)
4.31 B EUR
1.01 B EUR
1.15 B EUR
Jan 1, 2027 (e)
4.53 B EUR
1.05 B EUR
1.13 B EUR
Jan 1, 2028 (e)
4.63 B EUR
1.09 B EUR
1.10 B EUR
Jan 1, 2029 (e)
4.92 B EUR
1.16 B EUR
1.20 B EUR
Jan 1, 2030 (e)
4.97 B EUR
1.17 B EUR
1.32 B EUR

Ipsen Margins

Ipsen stock margins

The Ipsen margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Ipsen. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Ipsen.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
82.72 %
24.68 %
19.49 %
Jan 1, 2024
82.69 %
13.90 %
9.68 %
Jan 1, 2025
70.58 %
20.30 %
12.09 %
Jan 1, 2026 (e)
70.58 %
23.33 %
26.65 %
Jan 1, 2027 (e)
70.58 %
23.27 %
25.05 %
Jan 1, 2028 (e)
70.58 %
23.62 %
23.71 %
Jan 1, 2029 (e)
70.58 %
23.62 %
24.37 %
Jan 1, 2030 (e)
70.58 %
23.62 %
26.55 %

Ipsen Stock analysis

What does Ipsen do? Ipsen SA is a French biopharmaceutical company specialized in the development of drugs for the treatment of cancer, neurological disorders, and endocrine disorders. It was founded in 1929 by a pharmacist named Henri Beaufour and is headquartered in Paris. The history of Ipsen began with the production of extraction products from snake venom for the manufacturing of serum against tetanus and diphtheria. In the 1960s, the company started to focus on the production of hormones and peptides, with a focus on endocrine disorders. In the 1990s, Ipsen expanded its product portfolio to include oncology and neurological disorders. Ipsen's business model focuses on research and development of new drugs, as well as marketing of already established drugs in selected markets worldwide. The company employs around 5,700 employees and operates in more than 115 countries. Ipsen has two main business segments: specialty drugs and consumer healthcare. The specialty drugs segment focuses on the development and marketing of innovative therapies in the areas of oncology, endocrinology, and neuroscience. Ipsen's most well-known products include Somatuline, a drug for the treatment of acromegaly, and Decapeptyl, a drug for the treatment of prostate cancer and endometriosis. In the consumer healthcare segment, Ipsen is mainly specialized in the production of drugs for the treatment of gastrointestinal disorders and cold and flu symptoms. Some well-known brands include Smecta, a drug for diarrhea, and Nurofen, a pain reliever. Ipsen also has a strong presence in the field of aesthetic medicine, where the company operates a subsidiary called Ipsen Aesthetic. This subsidiary develops and markets products for the treatment of wrinkles and other signs of aging on the skin. Well-known brands of Ipsen Aesthetic include Dysport, a botulinum toxin product for the treatment of wrinkles, and the filler Restylane. Overall, Ipsen has established itself as a leading biopharmaceutical company focused on the development and marketing of products in specialized therapy areas. The company has a strong pipeline of new products in development and remains an important player in the pharmaceutical industry due to its strong scientific expertise and global presence. Ipsen is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Ipsen's EBIT

Ipsen's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Ipsen's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Ipsen's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Ipsen’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Ipsen stock

EBIT of Ipsen is 746.30 M EUR in 2026.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Ipsen

All Key Metrics — Ipsen